while the phase 3 ORION study in PSP is due to generate results in the middle of next year. AMX0014, meanwhile, is a calpain-2-targeting antisense drug, in late preclinical development ...
Neurosciences Unit, Institute of Child Health, University College London Medical School, 30 Guilford Street, London WC1N 1EH, UK Dr Rod C Scott, The Wolfson Centre, Mecklenburgh Square, London WC1N ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback